Literature DB >> 1955175

Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease.

F Seibold1, P Weber, H Jenss, K H Wiedmann.   

Abstract

The presence of antibodies against pancreatic juice (PAB) in patients with Crohn's disease has recently been reported. In our study sera from 273 patients with inflammatory bowel disease (222 with Crohn's disease, 51 with ulcerative colitis) have been examined for PAB and also for antibodies against gut tissues by means of indirect immunofluorescence. PAB were found in 68 of the 222 patients with Crohn's disease (31%), with titres ranging from 1/10 to 1/1280, and in only two patients with ulcerative colitis (4%), with titres of 1/20. None were found in 198 patients with various chronic inflammatory diseases and healthy control subjects. No differences were found between the PAB positive and negative patients when the following parameters were compared: disease activity (Crohn's disease activity index), involvement of bowel segments, incidence of extraintestinal disease, or treatment with anti-inflammatory drugs. Only seven of the patients with Crohn's disease had a history of pancreatic disease and of these, four had detectable pancreatic antibodies. Longitudinal observations of 40 patients with Crohn's disease showed a stable pattern for PAB, independent of disease activity and treatment. Partial characterisation of the PAB antigen, isolated from pancreatic juice, showed a trypsin sensitive macromolecular protein of more than 10(6) daltons not identical with a panel of defined exocrine pancreatic proteins. By contrast, antibodies against goblet cells (GAB) were found in 13 of 51 patients with ulcerative colitis (29%) and in none of the patients with Crohn's disease or control subjects. PAB were found as a highly specific serological marker for Crohn's disease and GAB for ulcerative colitis, but the relevance of PAB and GAB in the pathogenesis in Crohn's disease remains unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955175      PMCID: PMC1379384          DOI: 10.1136/gut.32.10.1192

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Immunohistochemical demonstration of pancreatic secretory proteins in human paneth cells.

Authors:  M Bohe; C Lindström; K Ohlsson
Journal:  Scand J Gastroenterol Suppl       Date:  1986

Review 2.  The immunologic basis of inflammatory bowel disease.

Authors:  W Strober; S P James
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

3.  Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis.

Authors:  T Hibi; S Aiso; M Ishikawa; M Watanabe; T Yoshida; K Kobayashi; H Asakura; S Tsuru; M Tsuchiya
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

4.  Antinuclear and pancreatic acinar cell antibodies in pancreatic diseases.

Authors:  P G Lankisch; H Koop; R Seelig; H P Seelig
Journal:  Digestion       Date:  1981       Impact factor: 3.216

5.  Fluorescent anti-colonic and E. coli antibodies in ulcerative colitis.

Authors:  H Marcussen
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

6.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  Idiopathic pancreatitis associated with inflammatory bowel disease.

Authors:  J A Seyrig; R Jian; R Modigliani; D Golfain; C Florent; B Messing; A Bitoun
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

8.  Pancreatitis associated with duodenal Crohn's disease.

Authors:  H S Altman; G Phillips; S Bank; H Klotz
Journal:  Am J Gastroenterol       Date:  1983-03       Impact factor: 10.864

9.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.

Authors:  H Malchow; K Ewe; J W Brandes; H Goebell; H Ehms; H Sommer; H Jesdinsky
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

10.  Immunological studies in ulcerative colitis. VIII. Antibodies to colon antigen in patients with ulcerative colitis, Crohn's disease, and other diseases.

Authors:  H E Carlsson; R Lagercrantz; P Perlmann
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

View more
  22 in total

1.  Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value.

Authors:  Evgenija Homsak; Dusanka Micetić-Turk; Borut Bozic
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

2.  Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  F Seibold; P Weber; R Klein; P A Berg; K H Wiedmann
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

3.  Idiopathic fibrosing pancreatitis associated with ulcerative colitis.

Authors:  E Nve; D Ribé; J Navinés; M J Villanueva; G Franch; A Torrecilla; J Blay; J M Badia
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

4.  Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Dimitrios Drygiannakis; Konstantinos Karmiris; Ioannis Drygiannakis; Sokratis Makreas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

5.  Antibody 'markers' in Crohn's disease: opportunity or overstatement?

Authors:  F Shanahan
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

6.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

7.  Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.

Authors:  Frauke Degenhardt; Andrea Dirmeier; Rocio Lopez; Sylvia Lang; Claudia Kunst; Dirk Roggenbuck; Dirk Reinhold; Silke Szymczak; Gerhard Rogler; Frank Klebl; Andre Franke; Florian Rieder
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

Review 8.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

9.  An elemental diet controls inflammation in indomethacin-induced small bowel disease in rats: the role of low dietary fat and the elimination of dietary proteins.

Authors:  Hideki Suzuki; Nozomi Hanyou; Ichiro Sonaka; Hisanori Minami
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

10.  Pancreatic autoantibodies in Crohn's disease: a family study.

Authors:  F Seibold; H Mörk; S Tanza; A Müller; C Holzhüter; P Weber; M Scheurlen
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.